In vivo experiments have shown that Phylogica’s cell penetrating peptide vaccine can trigger the immune system in mice to create defensive CD8+ T-cells at much higher levels than the current best in class product, CPP TAT. The CD8+ T-cells were also able to recognise and kill the target cells which expressed the triggering antigen with a high degree of efficiency.
Related Data & Insights
-
-
Rank Company Revenue 87th PYC Therapeutics $15.8m 90th GreenHy2 $15.0m 91st K2fly $14.8m 93rd Advanced Braking Technology $14.7m 94th DTI Group $13.3m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
14 Mar 2024
PYC taps investors for $75m
02 Jan 2024
Nedlands company joins Google in AI project
11 May 2023
Perth biotech company raises $30m
07 Nov 2022
Healthtech banks on rising numbers
15 Jul 2022
Exal Group buys $44m Freo warehouse
13 May 2022
Hockings hopes for blindness drug
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX